A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.

In a study of adults enrolled in a telehealth weight management program, 45% decreased their alcohol use after taking antiobesity medication.

Aquestive Therapeutics announced positive feedback from the FDA this week that keeps NDA planning for the novel epinephrine product on solid ground.

Your daily dose of the clinical news you may have missed.

Review authors emphasized the need for a more comprehensive approach to dementia management.

William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.

Your daily dose of the clinical news you may have missed.

With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

The proposal would expand antiobesity drug access for more than 7 million people with Medicare and Medicaid coverage.

Your daily dose of the clinical news you may have missed.

A woman in her early 50s presents with 6 hours of right sided pleuritic chest pain. What do the history and ECG suggest? What's yoru Dx?

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.

Comments on the draft recommendation can be submitted through December 23, 2024.

The patient shows no signs of trauma but is a poor historian so no further details are available. Do her vitals or ECG provide any clues to a Dx?

Your daily dose of the clinical news you may have missed.

Panelists discuss strategies for simplifying complex information for primary care physicians (PCPs), provide tips on how PCPs can effectively communicate evidence-based treatment options to patients, and outline actionable points and key takeaways to enhance patient care in managing menopause symptoms.

Panelists discuss alternative therapies for women who are not candidates for or choose not to use hormonal therapy, review nonhormonal treatment options recommended by the North American Menopause Society, and explore the growing importance of Level I evidence and consensus opinions in creating a more holistic view of available therapies, both hormonal and nonhormonal.

Panelists discuss key considerations for women taking hormonal therapy, emphasizing the importance of individualized treatment plans and shared decision-making to evaluate the risk-benefit profile of therapy.

Panelists discuss clinical trial data suggesting a small but higher incidence of endometrial hyperplasia or malignancy with fezolinetant, while no cases of endometrial hyperplasia or malignancy were observed with elinzanetant in a long-term safety study.